NASDAQ$LIVN
LivaNova PLC · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
LivaNova's Q4 2021 performance saw a slight increase in worldwide sales and achieved adjusted earnings per share, driven by growth in Neuromodulation and Cardiopulmonary segments.
LivaNova PLC reported a slight increase in worldwide sales from continuing operations for Q4 2021, with significant growth when excluding the divested Heart Valves business. The company's execution met or exceeded the high end of full-year guidance, driven by Neuromodulation and Cardiopulmonary sales. Adjusted diluted earnings per share was $0.57.
- Worldwide sales from continuing operations increased by 0.2% on a reported basis, and 1.8% on a constant-currency basis.
- Excluding the Heart Valves business, sales from continuing operations increased by 10.1% on a reported basis and 11.8% on a constant-currency basis.
- Fourth quarter adjusted diluted earnings per share from continuing operations was $0.57.
- The company expects worldwide net sales for full-year 2022 to grow between 3 and 5 percent on a constant-currency basis after excluding the impact of the Heart Valves divestiture.
Headline financials
Revenue & EPS history
LivaNova · Revenue · Quarterly
$270M
Revenue by segment
LivaNova · $265M total across 3 segments · Q4 2022
- Cardiopulmonary$137M—51.5%
- Neuromodulation$127M—47.9%
- Other Revenue$1.6M—0.6%
Forward guidance
LivaNova expects worldwide net sales for full-year 2022 to grow between 3 and 5 percent on a constant-currency basis after excluding the impact of the Heart Valves divestiture. Adjusted diluted earnings per share from continuing operations for 2022 are expected to be in the range of $2.50 to $2.80, assuming a share count of 54 million for full-year 2022. In 2022, the Company estimates that adjusted free cash flow will be in the range of $90 to $110 million.
Tailwinds
- Worldwide net sales for full-year 2022 to grow between 3 and 5 percent on a constant-currency basis after excluding the impact of the Heart Valves divestiture.
- Adjusted diluted earnings per share from continuing operations for 2022 are expected to be in the range of $2.50 to $2.80.
- Assumes a share count of 54 million for full-year 2022.
- Adjusted free cash flow will be in the range of $90 to $110 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+1.2%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+1.3%
Avg return
30 days after
58%
26 / 45 earnings
Positive
+23.3%
Q1 2025
Best reaction
-19.9%
Q3 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +15.1% | +21.7% | +25.5% | |
| Q4 2025 | +0.8% | +1.8% | -10.4% | |
| Q3 2025 | -5.8% | -5.7% | +17.5% | |
| Q1 2025 | +23.3% | +28.6% | +30.7% | |
| Q4 2024 | -15.8% | -15.9% | -20.0% | |
| Q3 2024 | -2.5% | -7.5% | -0.9% | |
| Q2 2024 | -5.8% | -11.8% | -1.8% | |
| Q1 2024 | +12.9% | +12.3% | +9.5% | |
| Q4 2023 | +6.9% | +6.4% | +6.4% | |
| Q3 2023 | -0.8% | -0.9% | -6.4% | |
| Q2 2023 | +7.0% | +9.1% | +4.0% | |
| Q1 2023 | +0.6% | -0.0% | -0.6% | |
| Q4 2022 | -9.6% | -12.1% | -23.6% | |
| Q3 2022 | +2.2% | +6.6% | +19.1% | |
| Q2 2022 | -3.0% | -2.2% | -13.9% | |
| Q1 2022 | -13.2% | -21.8% | -9.1% | |
| Q4 2021 | +7.9% | +9.4% | +8.6% | |
| Q3 2021 | +15.3% | +15.9% | +2.4% | |
| Q2 2021 | +8.0% | +7.1% | +1.1% | |
| Q1 2021 | +3.8% | +1.4% | +0.8% | |
| Q4 2020 | +3.5% | +3.6% | +2.6% | |
| Q3 2020 | +1.0% | -4.5% | +8.9% | |
| Q2 2020 | -11.0% | -17.2% | -14.9% | |
| Q1 2020 | -5.8% | -10.4% | -5.1% | |
| Q4 2019 | +3.3% | +5.2% | -34.6% | |
| Q3 2019 | -6.8% | -6.4% | +10.4% | |
| Q2 2019 | +5.8% | +1.7% | +2.5% | |
| Q1 2019 | +5.2% | +8.8% | +4.4% | |
| Q4 2018 | -4.2% | -3.1% | +0.0% | |
| Q3 2018 | +5.6% | +6.9% | -6.6% | |
| Q2 2018 | +12.2% | +10.3% | +14.0% | |
| Q1 2018 | -8.0% | -6.7% | +5.9% | |
| Q4 2017 | +2.4% | +0.8% | +1.1% | |
| Q3 2017 | +11.7% | +9.1% | +20.3% | |
| Q2 2017 | +1.4% | +1.5% | +7.7% | |
| Q1 2017 | +4.0% | +4.8% | +7.0% | |
| Q4 2016 | +4.2% | -2.0% | -2.8% | |
| Q3 2016 | -19.9% | -21.0% | -19.3% | |
| Q2 2016 | +14.9% | +11.1% | +12.0% | |
| Q1 2016 | -3.5% | — | — | |
| Q4 2014 | -0.0% | — | — | |
| Q4 2013 | -0.0% | — | — | |
| Q4 2015 | -1.1% | — | — | |
| Q2 2015 | +1.9% | — | — | |
| Q3 2015 | -10.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro